Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment

Neurology. 2004 Jan 13;62(1):158; author reply 158-9. doi: 10.1212/wnl.62.1.158.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
  • Animals
  • Astrocytes / drug effects
  • Astrocytes / metabolism
  • Clinical Trials as Topic
  • Corpus Striatum / drug effects
  • Disease Models, Animal
  • Microglia / drug effects
  • Microglia / metabolism
  • Minocycline / adverse effects
  • Minocycline / therapeutic use*
  • Motor Activity / drug effects
  • Neuroprotective Agents / adverse effects
  • Neuroprotective Agents / therapeutic use*
  • Oxidopamine
  • Parkinsonian Disorders / chemically induced
  • Parkinsonian Disorders / drug therapy*
  • Primates
  • Quinolinic Acid
  • Rats
  • Rats, Wistar
  • Substantia Nigra / drug effects
  • Treatment Failure

Substances

  • Neuroprotective Agents
  • Oxidopamine
  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
  • Quinolinic Acid
  • Minocycline